Nucleic acids encoding truncated soluble tumor necrosis factor

Details Nucleic acids encoding truncated soluble tumor necrosis factor Nucleic acids encoding truncated soluble tumor necrosis factor

2005-05-10

2010-06-08

Landsman, Robert (Department: 1647)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069100, C435S252300, C435S320100, C435S325000, C435S471000

Reexamination Certificate

active

07732587

ABSTRACT:
Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor necrosis binding proteins by recombinant genetic engineering techniques.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4522750 (1985-06-01), Ades et al.
patent: 4560649 (1985-12-01), Saxena et al.
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4670563 (1987-06-01), Jansen et al.
patent: 4675285 (1987-06-01), Clark et al.
patent: 4677027 (1987-06-01), Porath et al.
patent: 4696980 (1987-09-01), Porath
patent: 4760067 (1988-07-01), Firestone
patent: 4766106 (1988-08-01), Katre et al.
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4917888 (1990-04-01), Katre et al.
patent: 4931544 (1990-06-01), Katre et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 4966888 (1990-10-01), Saxena et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5089261 (1992-02-01), Nitecki et al.
patent: 5093475 (1992-03-01), Carroll et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5136021 (1992-08-01), Dembinski et al.
patent: 5153265 (1992-10-01), Shadle et al.
patent: 5162430 (1992-11-01), Rhee et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5171264 (1992-12-01), Merrill
patent: 5211945 (1993-05-01), Wallach et al.
patent: 5214131 (1993-05-01), Sano et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5344915 (1994-09-01), Le Marie et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5446090 (1995-08-01), Harris
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5453490 (1995-09-01), Hageman et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5569779 (1996-10-01), Sabahi et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5681566 (1997-10-01), Stevenson
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5712155 (1998-01-01), Smith et al.
patent: 5739208 (1998-04-01), Harris
patent: 5747639 (1998-05-01), Seely
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5811261 (1998-09-01), Wallach et al.
patent: 5863786 (1999-01-01), Feldmann et al.
patent: 5958409 (1999-09-01), Turk et al.
patent: 6143866 (2000-11-01), Brewer et al.
patent: 6270766 (2001-08-01), Feldman et al.
patent: 7238776 (2007-07-01), Hauptmann et al.
patent: 2009/0092608 (2009-04-01), Ni et al.
patent: 2003743 (1990-05-01), None
patent: 3910323 (1989-10-01), None
patent: 0040506 (1981-11-01), None
patent: 0092918 (1983-11-01), None
patent: 0094844 (1983-11-01), None
patent: 0154316 (1985-09-01), None
patent: 0169112 (1986-01-01), None
patent: 0225579 (1987-06-01), None
patent: 0247860 (1987-12-01), None
patent: 0259863 (1988-03-01), None
patent: 0308378 (1989-03-01), None
patent: 0154316 (1989-09-01), None
patent: 0334165 (1989-09-01), None
patent: 0343684 (1989-11-01), None
patent: 0372752 (1990-06-01), None
patent: 0386289 (1990-09-01), None
patent: 0393438 (1990-10-01), None
patent: 0395853 (1990-11-01), None
patent: 0398327 (1990-11-01), None
patent: 0412486 (1991-02-01), None
patent: 0417563 (1991-03-01), None
patent: 0418014 (1991-03-01), None
patent: 0422339 (1991-04-01), None
patent: 0433900 (1991-06-01), None
patent: 0512528 (1992-11-01), None
patent: 0526905 (1993-02-01), None
patent: 0622394 (1994-11-01), None
patent: 2218101 (1989-11-01), None
patent: 2246569 (1992-02-01), None
patent: 90339 (1989-05-01), None
patent: 62185029 (1987-08-01), None
patent: 02040399 (1990-02-01), None
patent: 8700056 (1987-01-01), None
patent: 8800837 (1988-02-01), None
patent: 8905145 (1989-06-01), None
patent: 8906546 (1989-07-01), None
patent: 8909220 (1989-10-01), None
patent: 9004413 (1990-05-01), None
patent: 9004650 (1990-05-01), None
patent: 9005755 (1990-05-01), None
patent: 9012874 (1990-11-01), None
patent: 9013575 (1990-11-01), None
patent: 9103553 (1991-03-01), None
patent: 9105047 (1991-04-01), None
patent: 9107190 (1991-05-01), None
patent: 9116437 (1991-10-01), None
patent: 9201002 (1992-01-01), None
patent: 9201472 (1992-02-01), None
patent: 9201474 (1992-02-01), None
patent: 9204384 (1992-03-01), None
patent: 9207076 (1992-04-01), None
patent: 9213095 (1992-08-01), None
patent: 9215682 (1992-09-01), None
patent: 9216221 (1992-10-01), None
patent: 9216555 (1992-10-01), None
patent: 9301498 (1993-01-01), None
patent: 9401483 (1994-01-01), None
patent: 9406476 (1994-03-01), None
patent: 9506058 (1995-03-01), None
patent: 9513312 (1995-05-01), None
patent: 9534326 (1995-12-01), None
patent: 9619459 (1996-06-01), None
patent: 9732607 (1997-09-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Banner et al., “Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation,” Cell 73: 431-45 (1993).
Cosman, “A family of ligands for the TNF receptor superfamily,” Stem Cells 12(5): 440-55 (1994).
Fu et al., “Model complexes of tumor necrosis factor-alpha with receptors R1 and R2,” Protein Eng. 8(12): 1233-41 (1995).
Naismith et al., “Seeing double: Crystal structures of the type I TNF receptor,” J. Mol. Recognit. 9(2): 113-17 (1996).
Nexo et al., “Lectin-Agarose Immobilization, a New Method for Detecting Soluble Membrane Receptors,” J. Biol. Chem. 254(18): 8740-43 (1979).
Nophar et al., “Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor,” EMBO J. 9(10): 3269-78 (1990).
Novick et al., “Soluble Cytokine Receptors are Present in Normal Human Urine,” J. Exp. Med. 170: 1409-14 (1989).
Novick et al., “Soluble Cytokine Receptors are Present in Normal Human Urine,” In: The Physiological and Pathological Effects of Cytokines, pp. 413-421 (1990).
Novick et al., “Purification of Soluble Cytokine Receptros from Normal Human Urine by Ligand-Affinity and Immunoaffinity Chromatography,” J. Chromatog. 510: 331-37 (1990).
Oliff et al., “Tumors Secreting Human TNF/Cachectin Induce Cachexia In Mice,” Cell 50: 555-63 (1987).
Olsson et al., “Isolation and Characterization of a Tumor Necrosis Factor Binding Protein from Urine,” Eur. J. Haematol. 42(3): 270-75 (1989).
Paleolog et al., “Deactivation of Vascular Endothelium By Monoclonal Anti-Tumor Necrosis Factor Antibody in Rheumatoid Arthritis,” Arthritis Rheum. 39: 1082-91 (1996).
Peetre et al., “A Tumor Necrosis Factor Binding Protein is Present in Human Biological Fluids,” Eur. J. Haematol. 41: 414-19 (1988).
Pennica et al., “Biochemical Properties of the 75-kDa Tumor Necrosis Factor Receptor,” J. Biol. Chem. 267 (29): 21172-78 (1992).
Peppel et al., “A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity,” J. Exp. Med. 174: 1483-89 (1991).
Piguet et al., “Tumor Necrosis Factor/Cachectin Plays a Key Role in Bleomycin-Induced Pneumophathy and Fibrosis,” J. Exp. Med. 170: 655-63 (1989).
Portoghese et al., “Opioid Agonist and Antagonist bivalent Ligands. The Relationship Between Spacer Length and Selectivity at Multiple Opioid Receptors,” J. Med. Chem. 29: 1855-61 (1986).
Powell et al., “The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS,” In

Affiliated with

Also associated with

Rating

Nucleic acids encoding truncated soluble tumor necrosis factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding truncated soluble tumor necrosis factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding truncated soluble tumor necrosis factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4204017